Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Natalie Staplin, Alistair Roddick, Jonathan Emberson, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101163-101163
Open Access | Times Cited: 57

Showing 26-50 of 57 citing articles:

Early Introduction of SGLT-2 Inhibitors to Improve Chronic Kidney Disease Care in People with or without Diabetes—Consensus by Indian Nephrologists
Manisha Sahay, Sunil Prakash, Manik Kataruka, et al.
Journal of Diabetology (2025) Vol. 16, Iss. 2, pp. 123-137
Open Access
6. CARDIO-RENAL PROTECTION IN TYPE 2 DIABETES
Stephen Colagiuri, Antonio Ceriello
Diabetes Research and Clinical Practice (2025), pp. 112150-112150
Closed Access
Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study
I‐Chieh Chen, Yen‐Wei Pai, Jun‐Fu Lin, et al.
Diabetes Research and Clinical Practice (2025), pp. 112167-112167
Open Access
Present and future directions in diabetic kidney disease
Christine P. Limonte, Matthias Kretzler, Subramaniam Pennathur, et al.
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 12, pp. 108357-108357
Open Access | Times Cited: 15
Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis
Rawa Bapir, Kamran Hassan Bhatti, Ahmed Eliwa, et al.
Archivio Italiano di Urologia e Andrologia (2023) Vol. 95, Iss. 2
Open Access | Times Cited: 9
Fournier's Gangrene in a Patient With CKD Without Diabetes Possibly Related to Sodium-Glucose Cotransporter 2 Inhibitor Therapy
Isabel Heidegger, Marit Zwierzina, Jan Boeckhaus, et al.
Kidney International Reports (2024) Vol. 9, Iss. 5, pp. 1531-1533
Open Access | Times Cited: 3
Fournier’s Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors
Ioana-Maria Suciu, Alin Greluș, Alina-Ramona Cozlac, et al.
Medicina (2024) Vol. 60, Iss. 5, pp. 837-837
Open Access | Times Cited: 2
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials
Christoph Wanner, Hristo Iliev, Nathália Dantas Duarte, et al.
Advances in Therapy (2024) Vol. 41, Iss. 7, pp. 2826-2844
Open Access | Times Cited: 2
Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
Edmund J. Lamb, Jonathan Barratt, Elizabeth Brettell, et al.
Health Technology Assessment (2024), pp. 1-169
Open Access | Times Cited: 2
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M.Y. Lee, Keith Gillis, Katriona Brooksbank, et al.
Circulation (2022) Vol. 146, Iss. 4, pp. 364-367
Open Access | Times Cited: 11
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials
Vikas S. Sridhar, Brendon L. Neuen, Robert A. Fletcher, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2331-2339
Open Access | Times Cited: 5
Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?
Emily P. McQuarrie, Keith Gillis, Patrick B. Mark
Current Opinion in Nephrology & Hypertension (2022) Vol. 31, Iss. 3, pp. 272-277
Open Access | Times Cited: 9
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors
Daniel S. Chapman, Parminder K. Judge, Rebecca J. Sardell, et al.
Kidney International (2023) Vol. 103, Iss. 4, pp. 787-790
Open Access | Times Cited: 4
Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
Ahmed Elkeraie, Saeed Alghamdi, Ali K. Abu‐Alfa, et al.
International Journal of Nephrology and Renovascular Disease (2024) Vol. Volume 17, pp. 1-16
Open Access | Times Cited: 1
Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors
Alessandro Bosi, Yang Xu, Anne‐Laure Faucon, et al.
Nephrology Dialysis Transplantation (2024)
Open Access | Times Cited: 1
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes
Anna Licata, Giuseppina Russo, Annalisa Giandalia, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 558-558
Open Access | Times Cited: 3
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
Junhao Lv, Luying Guo, Rending Wang, et al.
Kidney Diseases (2023) Vol. 9, Iss. 5, pp. 326-341
Open Access | Times Cited: 3
Expanding options of supportive care in IgA nephropathy
Dita Maixnerová, Jan Miroslav Hartinger, Vladimı́r Tesař
Clinical Kidney Journal (2023) Vol. 16, Iss. Supplement_2, pp. ii47-ii54
Open Access | Times Cited: 3
Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives
В. В. Салухов, G. R. Galstyan, T. A. Ilyinskay
Diabetes Mellitus (2022) Vol. 25, Iss. 3, pp. 275-287
Open Access | Times Cited: 4
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
Samy Hadjadj, Mark E. Cooper, Dominik Steubl, et al.
Kidney Medicine (2023) Vol. 6, Iss. 3, pp. 100783-100783
Open Access | Times Cited: 2
The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor–Associated Genitourinary Infections
Anthony Gerber, Victoria Rupp, Natalia Ryabenkova, et al.
Annals of Pharmacotherapy (2024) Vol. 58, Iss. 10, pp. 1013-1019
Closed Access


Urinary and Renal Research (2024) Vol. 5, Iss. 1
Open Access
Unveiling renoprotection: A comprehensive review of SGLT2 inhibitors, with emphasis on empagliflozin in the treatment of chronic kidney disease
Swathi Madagam
Urinary and Renal Research (2024) Vol. 5, Iss. 1
Open Access
Uso de inibidores do cotransportador sódio-glicose 2 e sua relação com infecções geniturinárias
Daniel Faria Pedrosa, Danilo Vilela Vilhena, Altielly Montes Machado, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 1, pp. 2875-2888
Open Access

Scroll to top